ONCT News and Press, Oncternal Therapeutics Inc. From 11/21/20

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks ended lower on Friday on raised concerns over the economic impact of the pandemic and the Treasury Department's new curtailing of emergency economic...

Gainers: Phoenix Tree (DNK) +91%.Naked Brand (NAKD) +64%.Kazia Therapeutics (KZIA) +32%.Micro Focus International (MFGP) +32%.BELLUS Health (BLU) +31%.InnSuites Hospitality Trust (IHT) +27%.FuelCell Energy (FCEL) +27%.Ashford Hospitality Trust (AHT) +24%.CIIG Merger (CIIC) ...

Oncternal Therapeutics (ONCT) -26% after raising 'bought deal' offering to $22.5M.PaySign (PAYS) -25% on Q3 earnings release.Interpace Biosciences (IDXG) -17%.New Concept Energy (GBR) -12%.Alterity Therapeutics (ATHE) -11%.Yunhong CTI (CTIB) -8%.Lowe's Companies (LOW)-6%&#...

Due to demand, Oncternal Therapeutics (ONCT) announces that the underwriter has agreed to increase the size of the previous public offering of ~7.3M common shares (from ~6.5M), to be priced at $3.10/share, for expected gross proceeds of ~$22.5M. Underwriter's over-allotment is an additional ~...

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously ...

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC...

Gainers: Akers Biosciences (AKER) +45%, Cidara Therapeutics (CDTX) +29%, Five Prime Therapeutics (FPRX) +24%, Zhongchao (ZCMD) +22%, Vaxart (VXRT) +22%.Losers: Applied Therapeutics (APLT) -12%, Soliton (SOLY) -13%, Harmony ...

Interim Phase 1 data in patients with relapsed/refractory Ewing sarcoma treated at the recommended Phase 2 dose of TK216 demonstrated two durable complete responses, with no relapses after complete response SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) --...

SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Stifel Virtual Healthcare Conference on Monday, November 16, 2020 at 2:00 p.m...

Gainers: Aptevo Therapeutics APVO +93%, Sundial Growers (SNDL) +93%, Oncternal Therapeutics (ONCT) +44%, Calliditas Therapeutics CALT +34%, Cogent Biosciences COGT +26%.Losers: Arcturus Therapeutics ARCT -39%, Quidel QDEL -32%, ...